Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 73Plasma cell 60Other hematologic neoplasm 27Genitourinary 6Gynecologic 4Gastrointestinal 4Myeloid 3Thoracic 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Endocrine 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Adenocarcinoma, Follicular 1

Interventions

lutetium Lu 177 dotatate 5surufatinib 4gallium Ga 68 dotatate 4Nivolumab 4Cisplatin 4pembrolizumab 3atezolizumab 3Everolimus 3selpercatinib 2olaparib 2lanreotide 2avelumab 2Radiotherapy 2Paclitaxel 2Etoposide 23-Iodobenzylguanidine 2veliparib 1vandetanib 1tivozanib 1tislelizumab 1spartalizumab 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1pegfilgrastim 1irinotecan sucrosofate 1iodophenyl metomidate 1fosbretabulin 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lenalidomide × Endocrine × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡